ClinicalTrials.gg
RecruitingNCT04113993Updated Jun 3, 2026

Bazedoxifene -Treatment for Women With Schizophrenia

A Phase 4 interventional study of Bazedoxifene Acetate and Placebo in Schizophrenia, Schizophreniform Disorders and Schizo Affective Disorder, sponsored by The Alfred. Recruiting at 1 site in Australia. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-06-03.

Sponsored by The Alfred · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2019; still recruiting 7 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 46 studies in Schizophrenia with a site in Australia — 3 open to participants now, 5 under way, 1 of them phase 3. Schizophrenia · Australia.

Planned enrollment
22nd of 41
160 · median 167
Started
2019
with 1 other
Phase 4
9 of 46
1 open now
Registered
41st of 46
by date
Lead sponsor
7 of 46
The Alfred

Among the 46 studies in Schizophrenia with a site in Australia, this one is the 22nd largest by planned enrollment of the 41 interventional ones that give a count, is one of 2 that started in 2019, is one of 9 in phase 4, and was the 41st registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

3 of the 46 studies in Schizophrenia with a site in Australia are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Schizophrenia with a site in Australia, or all of them as a file.
02

Study summary

To study the effect of adjunctive bazedoxifene - a selective estrogen receptor modulator (SERM) in a double blind, placebo-controlled adjunctive study in the treatment of women with schizophrenia. All patients receive standardized antipsychotic medication.

Read the detailed description

Despite advances in the treatment of schizophrenia, pharmacotherapy remains sub- optimal, and the prognosis for many patients is poor. We have pioneered work showing that estradiol has a positive role in the treatment of psychosis symptoms and cognitive deficits seen in people with schizophrenia. However, with the longer-term work from studies such as the Women's Health Initiative, it has become clear that long-term use of estradiol with progesterone may have associated increased risks of breast and other cancers. Hence, we began working with the Selective Estrogen Receptor Modulator - raloxifene, which appears to be safer for longer term use with respect to the development of breast and other cancers. Building on our and others work, raloxifene used as an adjunctive treatment in schizophrenia appears to produce inconsistent and varying responses in different sub-populations; gender, menopausal status, age, drug dose and delivery mode. We now propose to conduct a double-blind, randomized, placebo controlled trial of a third generation SERM - bazedoxifene - which is 4 times more selective for the alpha than the beta oestrogen receptor subtype. Bazedoxifene appears to be safer with respect to long term use than older SERMs, has additional actions on the glucocorticoid receptor, and together this different pharmacology speculatively has greater potential than other SERMs to impact favorably on both psychosis symptoms and cognition in men and women with schizophrenia. This study will test 160 women to determine if bazedoxifene, as an adjunctive hormone modulator, is effective for positive and cognitive symptoms of schizophrenia.

03

Conditions studied

  • Schizophrenia
  • Schizophreniform Disorders
  • Schizo Affective Disorder
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Physically well.
  • A current diagnosis of schizophrenia or related disorder.
  • 18- 65 years
  • Able to give .
  • PANSS total score between 40 and 90.
  • Documented normal PAP smear and pelvic examination in the preceding two years.
  • Stable psychotropic medication for previous 4 weeks
  • Normal breast screen (for women aged over 40 years)
  • IQ > 70 (as determined by the WAIS IV subtests)
  • English language proficiency (in order to provide informed consent and complete cognitive test battery)

Exclusion criteria

Exclusion Criteria:

  • Patients with known abnormalities in the hypothalamo-pituitary gonadal axis, thyroid dysfunction, central nervous system tumours, active or past history of a venous thromboembolic event.
  • Patients with a history of severe traumatic brain injury or significant neurological or unstable medical illness such as epilepsy and diabetes or known active cardiac, renal or liver disease; presence of illness causing immobilisation.
  • Patients whose psychotic illness is directly related to illicit substance use or who have a history of substance dependence during the last six months (with the exclusion of caffeine and/or nicotine dependence).
  • Women aged 40 or over who have not had a normal mammogram in the last 24 months
  • Use of any form of estrogen, progestin or androgen as hormonal therapy in preceding 4 weeks including the pill (excluding IUD or Hormone Implants).
  • Pregnant (HCG will be measured at screening)
  • Breastfeeding
  • Planned changes to psychotropic medication or psychotherapy regimen.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    Oral Bazedoxifene

    Oral Bazedoxifene dosed at 40 mg daily

    Drug: Bazedoxifene Acetate

  • Placebo comparator
    Placebo

    Identically packaged placebo capsule daily

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Schizophrenia symptoms

    Psychopathology rating scales to quantify psychotic and affective symptoms (PANSS)

    Time frame: 12 Weeks

Secondary outcomes

  1. Cognition

    Cognitive test battery to quantify changes in cognitive functioning (MATRICS)

    Time frame: 12 Weeks

07

Study locations

1 of 1 sites recruiting
  • Multidisciplinary Alfred Psychiatry Research Centre
    Melbourne, Victoria 3004, Australia
    Recruiting
    • Jayashri Kulkarni, MBBS,MPM,FRANZCP,PhD · Contactj.kulkarni@alfred.org.au · +61 3 9076 6924
    • Anthony deCastella, Dip App Sci, BA, MA · Contactanthony.decastella@monash.edu · +61 3 9076 6554
    • Jayashri Kulkarni, MBBS,MPM,FRANZCP,PhD · Principal investigator
    • Anthony deCastella, Dip AppSci,BA,MA · Sub investigator
    • Emorfia Gavrilidis, BAppSci · Sub investigator
    • Caroline Gurvich, DPsych FCCN MAPS · Sub investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2019 (actual). Primary completion is estimated for Dec 2026, 86 months after the start.

Of 71 non-industry phase 4 interventional studies under Schizophrenia, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 64. This study's planned 86 months is above that.

Counting every sponsor, half of 88 studies reached it within 39 months; a quarter within 20 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2019
First posted
Oct 3, 2019
StartActual
Oct 7, 2019
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Jun 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04113993
Lead sponsor
The Alfred
Collaborators
Monash University
Responsible party
Jayashri Kulkarni, Professor (Director of Multidisciplinary Alfred Psychiatry research centre, The Alfred) — Principal investigator
First posted
Oct 3, 2019
Start date
Oct 7, 2019
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jun 3, 2026

Study contacts

Anthony de Castella
Contact
Anthony.decastella@monash.edu
+61 390766564
MAPrc
Contact
maprc@monash.edu
+61 390766564

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bazedoxifene

Start the discussion